Meta-Analysis Shows Anlotinib Improves Survival and Response Rates in NSCLC Brain Metastases
核心洞察
A comprehensive meta-analysis of 18 studies involving 1,480 patients demonstrates that anlotinib significantly prolongs intracranial progression-free survival and overall survival in non-small cell lung cancer patients with brain metastases.
The multi-kinase inhibitor increased objective response rates by 55% and disease control rates by 33% compared to control treatments across the analyzed studies.
Safety analysis revealed anlotinib reduced nausea-vomiting risk by 48% while showing no significant differences in other adverse reactions compared to control groups.
A systematic review and meta-analysis published in Frontiers in Pharmacology provides compelling evidence that anlotinib, a multi-kinase inhibitor, offers significant clinical benefits for non-small cell lung cancer (NSCLC) patients with brain metastases. The comprehensive analysis of 18 studies encompassing 1,480 patients represents the most extensive evaluation to date of anlotinib's efficacy in this challenging patient population.
Significant Survival Benefits Demonstrated
The meta-analysis revealed that anlotinib significantly prolonged intracranial progression-free survival (IPFS) compared to control treatments, with a hazard ratio of 0.52 (95% CI: 0.36-0.75, P=0.0004). This translates to a 48% reduction in the risk of intracranial disease progression. Additionally, overall survival (OS) showed marked improvement with anlotinib treatment, demonstrating a hazard ratio of 0.69 (95% CI: 0.54-0.88, P=0.0003), representing a 31% reduction in mortality risk.
The survival data emerged from three studies included in the analysis, with results showing no heterogeneity between studies (I²=0%) for both endpoints, indicating consistent benefits across different patient populations and study designs.
Enhanced Response Rates Across Multiple Studies
Anlotinib demonstrated superior efficacy in achieving tumor responses, with the objective response rate (ORR) showing a relative risk of 1.55 (95% CI: 1.30-1.84, P<0.00001) compared to control treatments. This represents a 55% increase in the likelihood of achieving an objective response. The analysis included 15 studies for ORR assessment, though moderate heterogeneity was observed (I²=58%).
Disease control rates (DCR) also favored anlotinib treatment, with a relative risk of 1.33 (95% CI: 1.23-1.44, P<0.00001) across 13 studies. This indicates a 33% improvement in achieving disease control, with low heterogeneity between studies (I²=29%).
Favorable Safety Profile with Reduced Gastrointestinal Toxicity
The safety analysis revealed an unexpected benefit of anlotinib treatment: a significant reduction in nausea-vomiting compared to control groups. Seven studies contributed to this analysis, showing a relative risk of 0.52 (95% CI: 0.29-0.92, P=0.02), indicating a 48% reduction in the risk of experiencing nausea-vomiting. No significant differences were observed in other adverse reactions between anlotinib and control groups.
Comprehensive Methodology and Study Quality
The research team conducted an exhaustive literature search across multiple databases, including PubMed, EMBASE, Cochrane Library, Web of Science, and Chinese databases (CNKI, Wanfang, and VIP), covering publications from database inception through November 2024. The analysis included nine randomized controlled trials and nine retrospective cohort studies.
Study quality was rigorously assessed using the Cochrane risk of bias tool for randomized controlled trials and the Newcastle-Ottawa Scale for cohort studies. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) system was employed to evaluate evidence quality, with OS and DCR receiving moderate quality ratings, while IPFS, ORR, and nausea-vomiting outcomes received low quality ratings.
Clinical Implications for Brain Metastases Management
Brain metastases represent a significant challenge in NSCLC management and are a major factor contributing to treatment failure. The presence of brain metastases significantly impacts patient prognosis and quality of life, making effective treatments critically important for this patient population.
The study's findings suggest that anlotinib may offer a valuable therapeutic option for NSCLC patients with brain metastases, particularly given its ability to cross the blood-brain barrier and demonstrate intracranial activity. The combination of improved survival outcomes, enhanced response rates, and favorable safety profile positions anlotinib as a potentially important addition to the treatment armamentarium for this challenging clinical scenario.
The research was registered in the PROSPERO database (CRD42025632195), ensuring transparency and methodological rigor in the systematic review process. The authors acknowledged that the risk of bias in some included studies was unclear, highlighting the need for additional high-quality randomized controlled trials to further validate these findings.